ENCO-BRAF

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jun 4, 2023 → Oct 28, 2026

Cited window

Jun 4, 2023 → Oct 28, 2026

Retrieved

Oct 29, 2026

Title

A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer

Registry

NCT04526782

Study IDs

IFCT-1904

Sponsor

Intergroupe Francophone de Cancerologie Thoracique

Design

Phase 2 · Interventional, non randomized, parallel

Status

Active, not recruiting

Enrollment

119 estimated

Start

2021-01-19 actual

Primary completion

2025-07-16 actual

Primary endpoint

Objective response rate

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on first-line combination efficacy and the immaturity of progression-free survival and response-duration follow-up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –Nineteen of 37 original sources contain passages that were not fully assessed; additional relevant views may therefore be missing.
• –Discussion using other wording or leaving the trial unnamed may be absent, including treatment-decision commentary relevant to the same population.
• –The sources do not establish the prevalence of these views among HCPs. Reposts and source counts should not be interpreted as independent endorsements.
• –A full protocol and an exact-trial results publication were unavailable for this edition, limiting assessment of methods and reported outcomes against a complete study report.
• –Exact regulatory product information was unavailable. Approval, standard-of-care and access descriptions are presented as dated, attributed statements rather than independently confirmed jurisdictional conclusions.
• –Earlier combination studies, PHAROS, ENCO-BRAF results and practice anecdotes must remain separate; their figures do not form a pooled efficacy or safety estimate.
• –The October 2026 post and interview give different previously treated survival values, 37.5 and 35 months, without explaining the difference.

How reports are built and checked: Methods.

Last checked for new commentary Oct 29, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "ENCO-BRAF" (NCT04526782), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "enco-braf-04526782". If you cannot make requests, read https://www.erudio.com/reports/enco-braf-nct04526782.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04526782", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct04526782 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/enco-braf-nct04526782.json
curl https://www.erudio.com/reports/enco-braf-nct04526782.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "enco-braf-04526782" })